FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 342:1902-1904 June 22, 2000 Number 25 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

The pharmaceutical industry is under mounting scrutiny because of rapidly increasing expenditures for drugs in the United States. Drug expenditures are now the fastest-growing component of health care costs, increasing at the rate of about 15 percent per year.^1,2 They account for about 8 percent of health care spending, and at their current rate of increase, they will soon surpass spending for physicians' services and, for many health maintenance organizations (HMOs), the costs of hospitalization. The increase is due both to a greater use of drugs and to higher prices for individual drugs. Patients feel drug costs keenly, because they . . . [Full Text of this Article]

References

Related Letters:

The Pharmaceutical Industry — To Whom is It Accountable?
Holmer A. F., Reif M. C., Schwarting J. S., Bohrer R. A., Hayes T. A., Rightor N., Summers W. K., Driscoll J., Orient J. M., Jacobs C., Mehta D. J., Angell M.
Extract | Full Text  
N Engl J Med 2000; 343:1415-1417, Nov 9, 2000. Correspondence

This article has been cited by other articles:

• Leibing, A. (2009). Tense Prescriptions? Alzheimer Medications and the Anthropology of Uncertainty. Transcultural Psychiatry 46: 180-206 [Abstract]  
• Hartley, H., Coleman, C.-L. (2008). News media coverage of direct-to-consumer pharmaceutical advertising: implications for countervailing powers theory. Health (London) 12: 107-132 [Abstract]  
• Hartley, H. (2006). The 'Pinking' of Viagra Culture: Drug Industry Efforts to Create and Repackage Sex Drugs for Women. Sexualities 9: 363-378 [Abstract]  
• Foladori, G. (2005). The Challenge of Infectious Diseases to the Biomedical Paradigm. Bulletin of Science Technology Society 25: 145-158 [Abstract]  
• Curtis, P., Gaylord, S. (2005). Safety Issues in the Interaction of Conventional, Complementary, and Alternative Health Care. Complementary Health Practice Review 10: 3-31 [Abstract]  
• Armstrong, P. W., Newby, L. K., Granger, C. B., Lee, K. L., Simes, R. J., Van de Werf, F., White, H. D., Califf, R. M., for the Virtual Coordinating Centre for Global Col, (2004). Lessons Learned From a Clinical Trial. Circulation 110: 3610-3614 [Full Text]  
• Schieppati, A., Remuzzi, G. (2004). Fighting Renal Diseases in Poor Countries: Building a Global Fund with the Help of the Pharmaceutical Industry. J. Am. Soc. Nephrol. 15: 704-707 [Abstract] [Full Text]  
• DuVal, G (2004). Institutional ethics review of clinical study agreements. J. Med. Ethics 30: 30-34 [Abstract] [Full Text]  
• Mike, V. (2003). Evidence and the Future of Medicine. Eval Health Prof 26: 127-152 [Abstract]  
• Bayus, B. L., Erickson, G., Jacobson, R. (2003). The Financial Rewards of New Product Introductions in the Personal Computer Industry. Management Science 49: 197-210 [Abstract]  
• Relman, A. S., Bittl, J. A., Ferris, L. E., Korenman, S. K., Drazen, J. M., Curfman, G. D. (2002). Financial Associations of Authors. NEJM 347: 1043-1044 [Full Text]  
• Hartley, H. (2002). Promising Liberation but Delivering Business as Usual?. Sexualities 5: 107-113  
• Anderson, J. (2001). The Francois Rabelais School of Medicine. BMJ 323: 1456-1457 [Full Text]  
• Ford, N., Torreele, E., Folkers, G. K., Fauci, A. S. (2001). Neglected Diseases of Global Importance. JAMA 286: 2943-2944 [Full Text]  
• Liu, Y.-C., Huang, W.-K., Huang, T.-S., Kunin, C. M. (2001). Inappropriate Use of Antibiotics and the Risk for Delayed Admission and Masked Diagnosis of Infectious Diseases: A Lesson From Taiwan. Arch Intern Med 161: 2366-2370 [Abstract] [Full Text]  
• Ryden, L., Simoons, M.L., Bassand, J.P. (2001). Partnership in cardiovascular medicine. A key to success not only for professional organizations. Eur Heart J 22: 1839-1843  
• Davidoff, F. (2001). The Heartbreak of Drug Pricing. ANN INTERN MED 134: 1068-1071 [Full Text]  
• Birkett, D. J., Mitchell, A. S., McManus, P. (2001). A Cost-Effectiveness Approach To Drug Subsidy And Pricing In Australia. Health Aff (Millwood) 20: 104-114 [Abstract] [Full Text]  
• Holmer, A. F., Reif, M. C., Schwarting, J. S., Bohrer, R. A., Hayes, T. A., Rightor, N., Summers, W. K., Driscoll, J., Orient, J. M., Jacobs, C., Mehta, D. J., Angell, M. (2000). The Pharmaceutical Industry -- To Whom is It Accountable?. NEJM 343: 1415-1417 [Full Text]  
• Enck, R. E. (2000). Parenteral opioids and cost. AM J HOSP PALLIAT CARE 17: 292-293  
• Ross, L. F., Norton, J. W., Young, S. A., Lebowitz, J., Leong, G. B., Silva, J. A., Dillon, D. C., Jagger, J., Firlik, A. D., Lowry, D. W., Diamond, C., Ruane, T. J., Hagan, B. M., Miller, P. D., Angell, M. (2000). Is Academic Medicine for Sale?. NEJM 343: 508-510 [Full Text]